Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase 2b Trial.

Hans P M W Wildiers Anne C Armstrong Eveline Cuypere Florence Dalenc Luc Dirix Stephen Chan Frederic Marmé Carolina P Schröder Jens Huober Fran Ois P Duhoux Peter Vuylsteke Agnes Jager Etienne G C Brain Sherko Kuemmel Zsuzsanna Pápai Catharina Willemien Menke-van der Houven van Oordt Luca Perjesi Christian Mueller Chrystelle Brignone Frederic Triebel

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Although the primary endpoint, PFS, was not met, AIPAC confirmed expected pharmacodynamic effects and demonstrated excellent safety profile for efti. Overall survival was not significantly improved globally (2.9-month difference), but was significantly improved in exploratory biomarker subgroups, warranting further studies to clarify efti's role in patients with ET-resistant HER2- MBC.

Keyphrases